From a panel of anti-uPAR clones, we selected ATN-658 for further development based on demonstrating its ability to block multiple oncogenic signaling pathways, tumor growth, and metastasis in several xenograft tumor models21–23 ATN-658 was subsequently humanized (huATN-658; MNPR-101) and is now in late preclinical development. The gene discussed is PLAUR; the disease is neoplasm.